New antibody-drug conjugate shows early promise against all forms of melanoma

April 8, 2014

The investigational drug DEDN6526A, which is a new member of a class of drugs called antibody-drug conjugates, was safe, tolerable, and showed hints of activity against different forms of melanoma—cutaneous, mucosal, and ocular—according to results of a first-in-human phase I clinical trial presented here at the AACR Annual Meeting 2014, April 5-9.

"As one of the first clinical trials to test an antibody-drug conjugate for the treatment of melanoma, we were encouraged by the initial responses," said Jeffrey R. Infante, M.D., director of the drug development program at Sarah Cannon Research Institute in Nashville, Tenn. "We found DEDN6526A to have a well-tolerated safety profile, and more importantly, to benefit a substantial proportion of patients. It is particularly promising to see clinical activity in patients with mucosal as well as ocular melanoma, and we hope that patients who are enrolling in the ongoing expansion phase of the trial gain similar benefit."

Antibody-drug conjugates consist of an antibody attached to a toxic chemotherapy by a special linker that keeps the chemotherapy inactive. In the case of DEDN6526A, the antibody recognizes the protein endothelin B receptor (ETBR) and the toxic chemotherapy is monomethyl auristatin (MMAE). Infante explained that when administered to the patient, the antibody portion of DEDN6526A recognizes and attaches to ETBR, which is often present at elevated levels on the surface of tumor cells in patients with melanoma. The whole antibody-drug conjugate is then taken up by the cells and MMAE is released from the linker to become active, killing the .

"ETBR is expressed at elevated levels on about 50 percent of melanomas," continued Infante. "We can't be more precise about this just yet because we are still developing a good assay to measure ETBR levels."

Infante and colleagues enrolled patients with metastatic or unresectable melanoma in the dose-escalation phase of the trial. Each patient was administered DEDN6526A intravenously, once every three weeks. The initial dose tested was 0.3 mg/kg; the maximum-tolerated dose was determined to be 2.4 mg/kg, and this dose is being tested in the expansion phase of the trial.

Clinical benefit was observed by the researchers for 12 of the 19 patients who were assigned 1.8 mg/kg of DEDN6526A or more. Four of these patients, two with cutaneous melanoma and two with mucosal melanoma, had confirmed partial responses. The other eight patients, five with cutaneous melanoma, two with , and one with mucosal melanoma, had stable disease for six or more months. In some cases, disease was stable for a prolonged period; for example, one patient is currently approaching two years on the study, according to Infante.

The researchers found that the most specific adverse event related to the study drug was infusion-related reaction, which was mitigated by amending the protocol to allow patients to receive steroids before their DEDN6526A infusion. Other adverse events reported were fatigue, anemia, reduced numbers of immune cells called neutrophils, and neuropathy. According to Infante, these are all side effects that would be expected in patients being treated with toxic chemotherapy.

"With the initial findings, we have begun to look at whether clinical activity correlates with ETBR levels on a patient's tumor," said Infante. "Patients with all forms of melanoma expressing high levels of ETBR seem more likely to benefit from treatment with DEDN6526A, and we hope that further investigation of this biomarker for response to DEDN6526A will inform future development of this treatment."

Explore further: Biomarker identifies melanoma patients who may respond to immunotherapy MK-3475

Related Stories

Biomarker identifies melanoma patients who may respond to immunotherapy MK-3475

April 7, 2014
Among melanoma patients treated with the PD-1 inhibitor MK-3475, those whose tumors had the protein PD-L1 had better immune responses and higher survival rates, according to results presented here at the AACR Annual Meeting ...

Antibody-drug conjugate may provide new treatment option for pancreatic cancer patients

October 21, 2013
Patients with pancreatic cancer may benefit from an investigational member of an emerging class of anticancer drugs called antibody-drug conjugates, according to preclinical results presented here at the AACR-NCI-EORTC International ...

Antibody could be used to target tumor-causing protein, study shows

March 11, 2014
Cincinnati Cancer Center (CCC) and University of Cincinnati (UC) Cancer Institute researchers have found in a phase-1 study that patients with advanced melanoma and kidney cancer who were treated with a certain antibody that ...

Investigational drug may increase survival for some patients with advanced melanoma

March 4, 2014
An experimental drug aimed at restoring the immune system's ability to spot and attack cancer halted cancer progression or shrank tumors in patients with advanced melanoma, according to a multisite, early-phase clinical trial ...

Genetic testing beneficial in melanoma treatment

April 4, 2014
(Medical Xpress)—Genetic screening of cancer can help doctors customize treatments so that patients with melanoma have the best chance of beating it, according to the results of a clinical trial by researchers at the University ...

FDA approval of revolutionary two-drug combo to treat advanced melanoma

January 27, 2014
Moffitt Cancer Center researchers have laid the groundwork for a revolutionary new combination therapy for the treatment of advanced melanoma – melanoma that cannot be removed surgically or has spread to other areas of ...

Recommended for you

Researchers release first draft of a genome-wide cancer 'dependency map'

July 27, 2017
In one of the largest efforts to build a comprehensive catalog of genetic vulnerabilities in cancer, researchers from the Broad Institute of MIT and Harvard and Dana-Farber Cancer Institute have identified more than 760 genes ...

Cancer-death button gets jammed by gut bacterium

July 27, 2017
Researchers at Michigan Medicine and in China showed that a type of bacterium is associated with the recurrence of colorectal cancer and poor outcomes. They found that Fusobacterium nucleatum in the gut can stop chemotherapy ...

Long-sought mechanism of metastasis is discovered in pancreatic cancer

July 27, 2017
Cells, just like people, have memories. They retain molecular markers that at the beginning of their existence helped guide their development. Cells that become cancerous may be making use of these early memories to power ...

Blocking the back-door that cancer cells use to escape death by radiotherapy

July 27, 2017
A natural healing mechanism of the body may be reducing the efficiency of radiotherapy in breast cancer patients, according to a new study.

Manmade peptides reduce breast cancer's spread

July 27, 2017
Manmade peptides that directly disrupt the inner workings of a gene known to support cancer's spread significantly reduce metastasis in a mouse model of breast cancer, scientists say.

Glowing tumor technology helps surgeons remove hidden cancer cells

July 27, 2017
Surgeons were able to identify and remove a greater number of cancerous nodules from lung cancer patients when combining intraoperative molecular imaging (IMI) - through the use of a contrast agent that makes tumor cells ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.